October 10, 2017

Majority of Recurrent Prostate Cancer Patients' Treatment Plan Changed Following Fluciclovine 18F PET/CT

Blue Earth Diagnostics recently announced the results of a pre-planned interim analysis from an investigational clinical trial evaluating the impact of fluciclovine (18F) PET/CT imaging on clinical management of men with biochemically recurrent prostate cancer eligible for salvage therapy. {read more here}

Comments

Leave a Reply

Your email address will not be published. Required fields are marked *

CAPTCHA:      = 

Leave a Reply

Your email address will not be published. Required fields are marked *